The U.S. Supreme Court declined to hear a case challenging Bayer's Roundup weedkiller over cancer allegations, effectively blocking further legal action on the matter. This decision shapes the landscape for thousands of pending lawsuits against the agrochemical company with similar claims.
The ruling stems from cases where plaintiffs argued that glyphosate, Roundup's active ingredient, caused cancer. Bayer acquired Roundup's manufacturer, Monsanto, in 2018 for $63 billion, inheriting its legal liabilities. Lower courts had previously awarded substantial damages to some plaintiffs, but Bayer appealed those decisions.
By rejecting the petition, the Supreme Court left intact lower court rulings that largely favored Bayer in subsequent appeals. This move effectively closes a major legal avenue for cancer plaintiffs seeking compensation. The decision suggests the nation's highest court believes existing legal processes adequately addressed the claims without requiring Supreme Court intervention.
The implications ripple across the litigation landscape. Thousands of Roundup lawsuits remain pending in state and federal courts. Without Supreme Court precedent on the matter, these cases will proceed through lower courts using established standards. Some legal analysts view the rejection as a setback for plaintiffs, though others note that earlier jury verdicts favoring cancer patients remain significant.
The International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans" in 2015. Regulatory agencies in the U.S. and Europe maintain that Roundup is safe when used as directed, though scientific debate continues. Bayer has consistently disputed links between glyphosate exposure and cancer development.
For individuals who have used Roundup extensively over decades, particularly agricultural workers and homeowners, the Supreme Court's decision means pursuing claims now becomes harder. Remaining lawsuits will navigate state and federal courts without the definitive Supreme Court